As the world pushes for newer, innovative tech, there are many ways to invest in the future. Recently, autonomous drone stocks have yielded handsome returns. Mysterious drone sightings in the Northeastern U.S. helped drive this. Two companies working closely in this space are Red Cat (NASDAQ: RCAT.... |
Good MorningEquity markets rebounded on Friday to end the week down slightly from the end of 2024. The move may indicate market weakness, but that has yet to be seen. As it is, the market remains above critical support levels and aligned with uptrends that are expected to continue. Price action on the daily chart suggests the rally could resume next week, and there are reasons to think it will. Next week will bring another round of economic data likely to show solid labor markets and consumer health, and the following week will be the beginning of peak earnings season. With economic health and earnings growth in the picture, it is unlikely that the S&P 500 will fall far if it does at all.
Oil is reemerging as a risk. The price of WTI advanced more than 5% last week and is on track to hit the top of its trading range in early Q1. The move is driven by the expectation for Trump's policies and surprise stimulus in China. China increased wages for a large portion of its economy to invigorate consumption. The risk is that higher oil prices will reinvigorate inflation and keep the Fed from further lowering rates. Featured: The 7 Stocks Quietly Gaining Attention Right Now (Ad) 
| Industrials | |
As the world pushes for newer, innovative tech, there are many ways to invest in the future. Recently, autonomous drone stocks have yielded handsome returns. Mysterious drone sightings in the Northeastern U.S. helped drive this. Two companies working closely in this space are Red Cat (NASDAQ: RCAT... Read the Full Story |
| From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
| Energy | |
Multiple factors, including forecasts for an extremely cold winter and rising natural gas prices, are driving a surge in diesel prices. The Department of Energy/Energy Information Administration (DOE/EIA) reported a $0.027 increase in the average retail diesel price, reaching $3.503 a gallon to cl... Read the Full Story |
| Markets | |
Experts predict that the impact of climate change on everything from housing to public health will increase over time. A study by the Energy Policy Institute of the University of Chicago estimates that for every one degree Fahrenheit increase in average temperature, costs to the U.S. economy will ... Read the Full Story |
| From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
| Technology | |
After Google's parent, Alphabet (NASDAQ: GOOGL), announced a breakthrough in quantum computing with its Willow chip, stocks linked to quantum tech have soared. Rigetti Computing (NASDAQ: RGTI) has seen its value rise several times over in just a month. However, one company that has seen a less sub... Read the Full Story |
| Technology | |
The artificial intelligence (AI) market is experiencing exponential growth, and at the heart of this revolution lies the critical need for a solid infrastructure. Nebius Group N.V. (NASDAQ: NBIS) is a rising star in the AI infrastructure space, and the company is making waves with its unique AI-... Read the Full Story |
| From Our Partners | | SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors.
Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | | Read Tilson's free analysis and find out what to do with your money |
| Consumer Discretionary | |
Amazon (NASDAQ: AMZN), Meta Platforms (NASDAQ: AMZN), and Intuitive Surgical (NASDAQ: ISRG) are the stocks most sold by insiders in 2024, but investors should buy them all. While not closely related, they all are ground-breaking technology that has had a long-lasting impact on daily life. The effe... Read the Full Story |
| Consumer Discretionary | |
Rivian Automotive Inc. (NASDAQ: RIVN) stock is up more than 15% the morning after the company announced fourth-quarter deliveries that came in well above analysts’ estimates.
Better still, the electric vehicle (EV) manufacturer announced that it is no longer experiencing a component shor... Read the Full Story |
| Consumer Discretionary | |
Polarizing activist short-seller Hindenburg Research—known for its bombshell reports alleging corporate fraud and other malfeasance by companies including Nikola Corp. (NASDAQ: NKLA) and India's Adani Group—published on January 2, 2025, an article about its latest target: Carvana Co. (... Read the Full Story |
| Consumer Discretionary | | The stock market is a popularity contest in the short term but a weighing machine in the long term. At least, that’s what Warren Buffett and Benjamin Graham, the fathers of value investing, think today. Investors today can see this trend at play through the way that attention has flown from th... Read the Full Story |
| Utilities | |
Constellation Energy (NASDAQ: CEG) stock is up over 8% on January 2, 2025, following news of landmark contracts with the U.S. government. This price increase underscores the company's growing prominence in the clean energy sector and signals a potential turning point for nuclear energy's role in... Read the Full Story |
| Monday's Early Bird Stock Of The Day Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. | Should I Buy Vertex Pharmaceuticals Stock? VRTX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Thursday, October 08, 2026 at 6:38 PM.
Vertex Pharmaceuticals Bull Case -
Vertex Pharmaceuticals Incorporated recently crossed above its 200-day moving average of $477.12, a technical indicator that often signals a shift from a long-term downtrend to a potential uptrend, suggesting that recent buying pressure is strong enough to overcome previous selling pressure and that the stock is currently trading at $503.25.
-
The company demonstrated strong fundamental performance in its most recent earnings report on August 3rd, 2026, where it reported revenue of $3.33 billion, which exceeded analyst estimates of $3.23 billion, and achieved a year-over-year revenue growth of 12.5%, indicating robust demand for its therapies despite a slight miss in earnings per share.
-
Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of "Moderate Buy" and an average price target of $575.13, which represents significant upside potential from the current price, supported by recent price target increases from firms like UBS Group and Cantor Fitzgerald.
-
Vertex Pharmaceuticals Incorporated benefits from a low beta of 0.28, which measures the stock's volatility relative to the overall market, meaning it tends to be less volatile than the broader market and may offer a more stable investment profile during periods of market uncertainty.
-
Institutional investors continue to show confidence in the company, with 90.96% of the stock owned by institutional investors, and recent filings show that major holders like State Street Corp increased their positions by 1.2% in the second quarter, signaling long-term commitment to the company's growth strategy.
Vertex Pharmaceuticals Bear Case -
There is a notable pattern of insider selling, with multiple executives including EVP Ourania Tatsis and EVP Duncan McKechnie selling shares in July 2026, and CMO Carmen Bozic selling significant amounts of stock in May and June 2026, which can sometimes signal that insiders believe the stock is overvalued or that they are diversifying their personal wealth.
-
The company's earnings per share of $4.73 in the most recent quarter slightly missed the consensus estimate of $4.74, and while revenue beat expectations, the margin between actual and expected earnings suggests that cost pressures or operational challenges may be impacting profitability more than anticipated.
-
Short interest in the stock has been increasing, with shares shorted rising to 4,716,867 as of September 15, 2026, up from 4,659,749 in the previous month, indicating that a growing number of traders are betting against the stock's price appreciation, which could create downward pressure on the share price.
-
The stock is trading at a price-to-earnings ratio of 29.29, which is relatively high compared to many other pharmaceutical companies, suggesting that investors are paying a premium for future growth that may not be fully justified if the company fails to meet its ambitious pipeline goals or if the market sentiment shifts negatively.
-
Vertex Pharmaceuticals Incorporated faces integration risks from its recent acquisition of Crinetics, as mentioned in recent articles, which could divert management attention and resources away from core business operations and potentially lead to unforeseen costs or delays in product development.
| | View Today's Stock Pick |
|
| |
|
|
